Bal Pharma Ltd (BALPHARMA) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Bal Pharma Ltd on NSE and BSE, with an AI summary of each filing.
To consider and approve the financial results for the period ended September 30, 2026 and other business matters
Intimation · 11 Nov 2026, 5:30 am
BAL PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 11-Nov-2026 to consider and approve the Quarterly Unaudited Financial results of the Company for the period ended September 2026 and Other business.
Intimation · 11 Nov 2026, 5:30 am
Bal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2026 ,inter alia, to consider and approve unaudited (Standalone and Consolidated) ....
Intimation · 11 Nov 2026, 5:30 am
Bal Pharma Schedules Board Meeting for Q2 FY27 Financial Results Bal Pharma Limited has scheduled a meeting of its Board of Directors on 11th Nov'26. The board will inter alia consider and approve the unaudited standalone and consolidated financial results of the company for the second quarter and half year ended 30th Sep'26 (Q2 FY27).
Dividend payment Update - Intimation regarding disbursement of final dividend for the Fy 2025-26 and withholding of dividend in respect of shareholders with incomplete KYC / bank account details
Dividend · 13 Oct 2026, 5:22 pm
Bal Pharma Disburses FY26 Final Dividend, Withholds Payouts for Incomplete KYC Bal Pharma completed the disbursement of its final dividend of ₹1.20 per equity share (face value ₹10) for FY25–26 on 9th Oct'26 to eligible shareholders registered as of the record date, 17th Sep'26. Payouts to physical and demat shareholders with incomplete KYC, invalid, blocked, or closed bank accounts have been withheld per SEBI norms. Undisbursed amounts will transfer to the Unpaid Dividend Account after 30 days, with release contingent upon submission and verification of updated KYC and banking details.
Change in Designation of Directors and Reconstitution of Statutory Committee with effective from 01st October 2026 as approved members at 39th AGM of Company held on 24th September 2026 ....
Change in Management · 25 Sept 2026, 11:30 pm
Enclosed Voting Result and Scrutinizers Report of 39th AGM held on 24th September 2026
Annual General Meeting · 25 Sept 2026, 11:20 pm
Enclosed Proceedings of the AGM of Bal Pharma Limited held on 24th September 2026
Annual General Meeting · 24 Sept 2026, 11:46 pm
Clarification regarding Movement in Price asper attachment
Others (Uncategorized) · 10 Sept 2026, 11:39 pm
Bal Pharma Clarifies Undisclosed Material Information Not Driving Recent Share Price Volatility Bal Pharma clarified on 10th Sep'26, in response to surveillance inquiries from NSE and BSE, that it holds no undisclosed price-sensitive or material information driving the recent significant movement in its scrip. The company confirmed full compliance with SEBI LODR disclosure norms within stipulated timelines, noting that no pending announcements or reportable events exist. Management emphasized that the share price volatility is purely natural, market-driven, attributable to prevailing market conditions, and completely disconnected from company management.
The Exchange has sought clarification from Bal Pharma Ltd on September 10, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant information ....
Others (Uncategorized) · 10 Sept 2026, 11:11 pm
Confirming the Allotment of Convertible Warrants on Preferential basis
Others (Uncategorized) · 07 Sept 2026, 11:46 pm
Bal Pharma Allots 10 Lakh Convertible Warrants to Promoter Bal Pharma Limited approved the preferential allotment of 10,00,000 convertible warrants at ₹84 per warrant to promoter Shailesh Siroya on 7th Sep'26, aggregating to ₹8.40 Cr, following receipt of 25% upfront subscription money (₹2.10 Cr). Each warrant is convertible into one equity share (face value ₹10 at a ₹74 premium) within 18 months upon paying the remaining 75%. Post full conversion, the promoter's shareholding will increase from 17.24% (27,45,459 shares) to 20.89% (37,45,459 shares).
In Continuation of Previous intimation hereby informing 17th September 2026 fixed as Record date for payment of final dividend and communication to shareholders regarding TDS on dividend payment
Dividend · 27 Aug 2026, 7:59 pm
Bal Pharma Sets Record Date for FY26 Final Dividend Bal Pharma has fixed 17th Sep'26 as the record date to determine shareholder eligibility for the FY 2025-26 final dividend. The company declared a dividend of Rs. 1.20 per equity share, which is 12% on the face value of Rs. 10 per share. The dividend will be paid on or after 24th Sep'26 to eligible members holding shares on the record date, subject to approval at the upcoming AGM. The announcement also includes details regarding TDS on the dividend payment.
Bal Pharma Limited Annual Report 2026
Others (Uncategorized) · 26 Aug 2026, 11:18 pm
39th AGM of the Company Scheduled on 24th September 2026. Notice copy enclosed
Annual General Meeting · 26 Aug 2026, 11:05 pm
This is to inform that 39th AGM of Bal Pharma Limited Scheduled to be held on Thursday 24th September 2026 at 11.00 AM through VC Mode.
Annual General Meeting · 26 Aug 2026, 10:50 pm
This is in Continuation of Company earlier intimation made in connection with allotment of warrants , hereby clarify that utilization of net proceeds or tenure of warrants is 18 month from ....
Others (Uncategorized) · 25 Aug 2026, 4:27 pm
Bal Pharma Clarifies Timeline for Preferential Issue Proceeds Bal Pharma clarified on Aug 25, '26 that the timeline for utilising net proceeds from its preferential issue of Convertible Warrants is 18 months from the allotment date. This is subject to in-principle approval from stock exchanges. The company confirmed there is no change in the previously stated objects or manner of utilisation for the proceeds, with the clarification being issued solely to specify the timeline due to the warrants' 18-month tenure.
In Continuation of Outcome of Board meeting dated August 12 2026 , Published Unaudited Financial result for the quarter ended 30th June 2026 and IEPF Notice in Financial express and Sanjevani ....
Outcome · 13 Aug 2026, 9:45 pm
Bal Pharma Publishes Q1FY27 Results and IEPF Transfer Notice Bal Pharma published its unaudited standalone and consolidated financial results for the quarter ended Jun 30, 2026, in newspapers on Aug 13, 2026, following board approval on Aug 12, 2026. Concurrently, the company issued a notice regarding the mandatory transfer of equity shares to the Investor Education and Protection Fund (IEPF) Authority. This applies to shareholders with dividends unclaimed since FY 2018-19. Shareholders must claim their shares and dividends by Oct 30, 2026, to avoid the transfer to the IEPF demat account.
Enclosed Financial Result for the First quarter ended 30th June 2026 together with Limited Review Report as submitted by Statutory auditor
Financial Result · 13 Aug 2026, 12:05 am
Board of directors of the Company met on Wednesday, August 12 2026 inter alia transacted the following business. 1. Considered and approved the unaudited Financial Results (Standalone ....
Outcome · 12 Aug 2026, 11:56 pm
Bal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve Pursuant to Regulation 29 and other ....
Intimation · 12 Aug 2026, 5:30 am
Bal Pharma Board Meeting Scheduled to Approve Q1 FY27 Results Bal Pharma has scheduled a Board of Directors meeting on 12 Aug'26. The primary agenda is to consider and approve the unaudited standalone and consolidated financial results for the first quarter ending 30 Jun'26 (Q1 FY27). The meeting will also address other matters with the permission of the Chair.
Company Providing opportunity to shareholders to Submit their Comments on Corrigendum to the Postal ballot notice
Others (Uncategorized) · 30 Jul 2026, 10:36 pm
Bal Pharma Offers Shareholders Comment Period on Postal Ballot Corrigendum Bal Pharma Limited announced on 30 Jul'26 that shareholders who voted before the Corrigendum to the Postal Ballot Notice (issued 23 Jul'26) have a 48-hour window to submit comments or objections. This is in response to stock exchange observations and aims to ensure transparency. Shareholders who previously voted are also given an opportunity to revise or modify their votes. The remote e-voting facility for the postal ballot remains open until 5:00 PM (IST) on 08 Aug'26.
In Continuation of Postal Ballot Notice dated 09th July 2026 , Submitting Corrigendum as integral part to the Said Notice.
Others (Uncategorized) · 23 Jul 2026, 11:55 pm
Bal Pharma Revises Preferential Warrant Issue Price to Promoter Bal Pharma has issued a corrigendum revising terms for its preferential issue of 10,00,000 convertible warrants to promoter Mr. Shailesh Siroya. The issue price is increased from ₹81 to ₹84 per warrant, raising the total consideration to ₹8.40 Cr from ₹8.10 Cr. Proceeds will part-finance a new ₹300 Cr greenfield API manufacturing facility in Yadgiri, Karnataka, with funds to be utilized by 31st Dec'27. Post-conversion, the promoter's stake (Mr. Shailesh Siroya) will increase from 17.24% to 20.89% on a fully-diluted basis.
This is with reference to our earlier intimation dated 27th May 2026 regarding appointment of Mr. Shreepada ML as company secretary and compliance officer of the company pursuant to the ....
Change in Management · 24 Jun 2026, 10:11 pm
Bal Pharma Appoints New Company Secretary and Compliance Officer Bal Pharma Limited announced that Mr. Shreepada ML has commenced his duties as the new Company Secretary and Compliance Officer, effective 23rd Jun'26. This follows the Board of Directors' approval for his appointment on 27th May'26. He will serve as a Key Managerial Personnel (KMP) for the company, fulfilling a crucial governance role. The change in key personnel is a regulatory disclosure under SEBI's Listing Obligations and Disclosure Requirements regulations.
Filing of Statement of deviation & variation is not applicable to the Company for the quarter ended 31.03.2026.
Others (Uncategorized) · 29 May 2026, 6:09 pm
Bal Pharma: No Fund Utilization Deviation for Q4 FY26 Bal Pharma Limited confirmed on 25 May'26 that the statement of deviation or variation in fund utilization is not applicable for the quarter ended 31 Mar'26. The company stated it has not raised funds through any public issue, rights issue, preferential issue, or QIP. Furthermore, no proceeds from any previous issues were outstanding for utilization during the specified quarter. This filing complies with Regulation 32(1) of SEBI (LODR) Regulations, 2015, and indicates no discrepancy in the use of raised capital.
Audited financial results of the company for the quarter and financial year ended 31.03.2026.
Financial Result · 28 May 2026, 12:13 am
Bal Pharma Q4FY26 Results, Dividend & Warrant Issue Bal Pharma's board approved FY26 results, recommending a dividend of ₹1.20/share (12%). The company will also issue 10,00,000 warrants preferentially to promoters and grant 5,00,000 ESOPs. For Q4FY26 (standalone), Net Profit rose 91% YoY to ₹370.02 lakhs, while Revenue from Operations increased 2.6% YoY to ₹8,391.76 lakhs. FY26 standalone Net Profit was ₹675.12 lakhs, down 13.4% YoY. The board also appointed Mr. Shreepada ML as the new Company Secretary effective 27 May'26.
Board of Directors of the Company has met today and transacted following business, 1. Approved audited financial results of the Company for the quarter and financial year ended 31.03.2026. 2.Recommend ....
Outcome · 28 May 2026, 12:00 am
Bal Pharma Ltd - Financial Result for the Quarter ended 31st Mar'26 (Consolidated, INR Lakh) ■ Revenue: 8,408 (+2.7% YoY | -4.1% QoQ) ■ EBITDA: 1,057 (+38.3% YoY | +10.7% QoQ) ■ EBITDA Margin (%): 12.6 (+324 bps YoY | +168 bps QoQ) ■ PAT: 359 (-33.9% YoY | +101.9% QoQ) ■ EPS (INR): 2.26 (-33.5% YoY | +101.8% QoQ)